MYX Mayne Pharma Group Ltd
- 4.720
- -0.050-1.05%
Mayne Pharma Group Ltd News
Why Appen, Mayne Pharma, Playside, and PYC Shares Are Storming Higher
It has been a tough finish to the week for the S&P/ASX 200 Index (ASX: XJO). In afternoon trade, the benchmark index is down 1.2% to 7,719 points.
Mayne Pharma Reiterates H2 FY24 Outlook in Wake of Change Healthcare Cyberattack
Mayne Pharma Group (ASX:MYX) said a cyberattack on US medical claims clearing house Change Healthcare in February has no material impact on the company as it reiterated its financial guidance for the
Cyberattack Only a Temporary Setback for Mayne Pharma -- Market Talk
0127 GMT - Mayne Pharma keeps its bull at Wilsons, where analysts see impact from a recent U.S. healthcare cyberattack as only a temporary setback. The Wilsons analysts tell clients in a note that the
Mayne Pharma Price Target Cut 4% to A$7.09/Share by Wilsons
Mayne Pharma Price Target Cut 4% to A$7.09/Share by Wilsons
Mayne Pharma Group Limited's (ASX:MYX) Largest Shareholders Are Individual Investors With 38% Ownership, Institutions Own 33%
Mayne Pharma Group's Nextstellis Oral Contraceptive Receives Two Additional US Patents
Mayne Pharma Group (ASX:MYX) said that the US Patent and Trademark Office has granted patent numbers 11,964,055 and 11,957,694, providing additional protection to the Nextstellis oral contraceptive fo
Investors in Mayne Pharma Group (ASX:MYX) Have Seen Respectable Returns of 93% Over the Past Year
Analysts Expect Breakeven For Mayne Pharma Group Limited (ASX:MYX) Before Long
Mayne Pharma Upgraded to Buy From Hold by Canaccord Genuity
Mayne Pharma Upgraded to Buy From Hold by Canaccord Genuity
Mayne Pharma Upgraded to Overweight From Market Weight by Wilsons
Mayne Pharma Upgraded to Overweight From Market Weight by Wilsons
Mayne Pharma Price Target Raised 34% to A$7.38/Share by Wilsons
Mayne Pharma Price Target Raised 34% to A$7.38/Share by Wilsons
Why Alumina, Kogan, Mayne Pharma, and Suncorp Shares Are Racing Higher
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and dropped into the red. At the time of writing, the benchmark index is down slightly to 7,642.4 points.
Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15%
Mayne Pharma Group's (ASX:MYX) booked a net loss attributable to equity holders of AU$70.6 million in the half-year ended Dec. 31, 2023, against an attributable profit of AU$290.0 million from a year
Mayne Pharma Had A$146.8 Million in Cash at End-December
Mayne Pharma Had A$146.8 Million in Cash at End-December
Mayne Pharma Says Won't Pay an Interim Dividend
Mayne Pharma Says Won't Pay an Interim Dividend
Mayne Pharma 1H Net Loss A$70.6 Million
Mayne Pharma 1H Net Loss A$70.6 Million
Mayne Pharma Price Target Raised 38% to A$5.50/Share by Wilsons
Mayne Pharma Price Target Raised 38% to A$5.50/Share by Wilsons
Mayne Pharma Price Target Raised 25% to A$4.00/Share by Wilsons
Mayne Pharma Price Target Raised 25% to A$4.00/Share by Wilsons
Mayne Pharma Gets Additional US Patent for Contraceptive
Mayne Pharma Group (ASX:MYX) received a notice of issue for a new patent granted by the US Patent and Trademark Office. The allowed claims provide additional patent protection to the NEXTSTELLIS formu
Strong Week for Mayne Pharma Group (ASX:MYX) Shareholders Doesn't Alleviate Pain of Five-year Loss
Analysis
Price Target
No Data
